Related Experiment Video
Updated: Jan 9, 2026
Author Spotlight: Replicating Human Osteosarcoma Progression in Immunodeficient Mice for Cancer Study
Published on: March 22, 2024
Therapeutic efficacy of oncolytic adenovirus YSCH-01 in osteosarcoma evaluated in PDX and CDX mouse models
Hanqiang Jin1,2, Ruoyu Chen3, Yonggang Wang4
1Department of Orthopedics, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Abstract:
YSCH-01, a recombinant L-IFN oncolytic adenovirus based anticancer drug with dual anti-tumor effects, has displayed significant antitumor properties in cancer treatment. However, its specific role in osteosarcoma and the underlying mechanisms remain under studied. Therefore, we analyzed clinical samples and performed experiments using osteosarcoma cell lines in both in vitro and in vivo settings. At the RNA and protein levels, the expression of L-IFN gene carried by YSCH-01 showed the potential antitumor properties. RNA-seq analysis of tumor samples treated with YSCH-01 provided insights into the altered gene expression profiles and signaling pathways, shedding light on the molecular basis of its antitumor effects. Those findings demonstrated that YSCH-01 displayed dose-dependent infectivity with different levels of efficacy and a significant inhibition of osteosarcoma cell proliferation. In both cell line and patient derived xenograft models, YSCH-01 exhibited potent therapeutic effects with the activated type I interferon signaling pathway in tumor tissues, particularly in terms of its distant effects. Furthermore, this study found out the key signal pathways through which YSCH-01 exerts its antitumor effects in osteosarcoma, which pinpointed potential therapeutic targets by identifying the type I interferon signaling pathway as the candidate molecular markers and their correlation with patient outcomes, positioning YSCH-01 as a promising candidate for osteosarcoma treatment.
Insights
YSCH-01, an oncolytic adenovirus, effectively inhibits osteosarcoma cell growth and activates the type I interferon pathway. This dual-action drug shows promise as a novel therapeutic for osteosarcoma.
Area of Science:
- Oncolytic virotherapy
- Cancer biology
- Immunotherapy
Background:
- Osteosarcoma treatment remains challenging.
- The therapeutic potential of YSCH-01, a recombinant L-IFN oncolytic adenovirus, in osteosarcoma is not well understood.
- Investigating the mechanisms of YSCH-01 is crucial for its clinical application.
Purpose of the Study:
- To evaluate the efficacy of YSCH-01 in osteosarcoma.
- To elucidate the underlying molecular mechanisms of YSCH-01's antitumor effects.
- To identify potential therapeutic targets and biomarkers for osteosarcoma treatment.
Main Methods:
- Analysis of clinical osteosarcoma samples.
- In vitro and in vivo experiments using osteosarcoma cell lines and patient-derived xenografts.
- RNA and protein expression analysis, including RNA-seq.
- Assessment of type I interferon signaling pathway activation.
Main Results:
- YSCH-01 demonstrated dose-dependent infectivity and significant inhibition of osteosarcoma cell proliferation.
- RNA and protein expression confirmed the antitumor potential of the L-IFN gene in YSCH-01.
- YSCH-01 activated the type I interferon signaling pathway in tumor tissues, showing potent therapeutic effects and distant antitumor activity.
- RNA-seq revealed altered gene expression profiles and signaling pathways affected by YSCH-01.
Conclusions:
- YSCH-01 exhibits significant antitumor effects in osteosarcoma through dual mechanisms.
- The type I interferon signaling pathway is a key mediator of YSCH-01's efficacy and a potential biomarker for patient outcomes.
- YSCH-01 represents a promising therapeutic candidate for osteosarcoma treatment.
